26872-84-4

Usage

Uses

Used in Pharmaceutical Industry:
N-Cyclohexyl-beta-alanine is used as a pharmaceutical intermediate for the synthesis of various drugs, contributing to the development of new medications.
Used in Respiratory Conditions:
N-Cyclohexyl-beta-alanine is used as a bronchodilator for the treatment of respiratory conditions, helping to alleviate symptoms by relaxing and widening the airways.
Used in Cardiovascular Conditions:
N-Cyclohexyl-beta-alanine is used as a vasodilator for the treatment of cardiovascular conditions, promoting the relaxation of blood vessel walls and improving blood flow.
Used in Cognitive Function Improvement:
N-Cyclohexyl-beta-alanine is studied for its potential role in improving cognitive function, suggesting its use in enhancing brain performance and mental processes.
Used as an Anti-Inflammatory Agent:
N-Cyclohexyl-beta-alanine is being investigated for its potential as an anti-inflammatory agent, indicating its use in reducing inflammation and associated symptoms.
Used in Enhancing Physical Performance:
N-Cyclohexyl-beta-alanine is researched for its ability to enhance physical performance and reduce fatigue, making it a candidate for use in sports and physical training applications.
However, further research is needed to fully understand the potential therapeutic benefits and safety profile of N-Cyclohexyl-beta-alanine.

InChI:InChI=1/C9H17NO2/c11-9(12)6-7-10-8-4-2-1-3-5-8/h8,10H,1-7H2,(H,11,12)

Upstream product

• 57-57-8 β-Propiolactone 
• 108-91-8 cyclohexylamine 
• 79-10-7 acrylic acid 
• 77-78-1 dimethyl sulfate 
• 6635-61-6 3-cyclohexylamino-propionic acid ethyl ester 
• 292638-85-8 acrylic acid methyl ester 

Downstream Products

• 114084-71-8 1-hydroxy-3-cyclohexylaminopropylidenediphosphonic acid 
• 51733-84-7 N-Cyclohexyl-α-sulfo-β-alanin 

Relevant academic research and scientific papers

PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN

The invention provides a parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/amaliorating agent that has a function such as parakeratosis inhibition, pore shrinkage, or rough skin -inhibition/abatement, poses no safety problems such as sensory irritation, and is very safe, and further provides an external composition for skin to which a compound having the above-mentioned function has been added. The parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/amaliorating agent comprises one or more compounds selected from the group consisting of β-alanine derivatives and salts thereof. The external composition for skin comprises the one or more compounds selected from the group consisting of β-alanine derivatives and salts thereof as the above-mentioned parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/amaliorating agent.

WRINKLE-IMPROVING AGENT

The invention provides a novel wrinkle-improving agent that has an effect of improving wrinkles, that does not entail problems of safety or pain even when applied to the skin, and that contains a very safe substance as an active component. A discovery was made that N-benzoyl-β-alanine, other specific β-alanine derivatives, and salts thereof have a wrinkle-improving effect, whereby a wrinkle-improving agent containing as an active component one, two, or more types of compounds selected from the group composed of these specific β-alanine derivatives and the salts thereof was developed.

New N-substituted 1-hydroxy-3-aminopropylidenediphosphonic acids

N-Substituted 1-hydroxy-3-aminopropylidenediphosphonic acids were synthesized. Their acid-base and complexation properties toward a wide series of metal cations in water were investigated.

Diphosphonate derivatives, pharmaceutical compositions and methods of use

The present invention provides disphosphonates of the general formula: STR1 wherein R1 is a straight-chain or branched, saturated or unsaturated aliphatic hydrocarbon radical of 1-9 carbon atoms which is optionally substituted by phenyl or cyclohexyl, R2 is cyclohexyl or cyclohexylmethyl, benzyl or a straight-chained or branched, saturated or unsaturated aliphatic hydrocarbon of 4 to 18 carbon atoms which is optionally substituted by phenyl or oxygen wherein the oxygen can be esterified or etherified, R3 is hydrogen or a straight-chain or branched alkyl of 1-4 carbon atoms, X is a straight-chain or branched alkylene chain of 1-6 carbon atoms and Y is hydrogen, hydroxyl or an amino group optionally substituted by alkyl radicals of 1-6 carbon atoms; as well as the pharmacologically acceptable salts thereof. The present invention also provides processes for the preparation of these diphosphonic acid derivatives and pharmaceutical compositions containing them for the prophyllaxis treatment of diseases or disturbances of calcium metabolism such as osteoporsis, Pagets disease, Bechterew's disease, bone metastases, urolithiasis, heterotropic ossifications, rheumatoid arthritis, osteoarthritis and degenerative arthrosis.